Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma

Abuelgasim, Khadega A.; Alzahrani, Mohsen; Alsharhan, Yousef; Khairi, M. R. A.; Hommady, Mohammed H; Gmati, Giamal; Salama, Hind; Ali, Osama; Alahmari, Bader; Masuadi, Emad; Alaskar, Ahmed; Alhejazi, Ayman; Damlaj, Moussab

doi:10.1038/s41409-019-0454-z

Cited by 16 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A number of groups have shown that Bv can feasibly be combined with ESHAP, IGEV, DHAP and bendamustine among others [12] , [13] , [14] , [15] . Such combinations carry important implications for two reasons; first, deeper responses particularly CMR prior to HCT is an important goal to attain as eluted to above.…”

Section: Discussionmentioning

confidence: 99%

“…The antibody drug conjugate (ADC) Brentuximab vedotin (Bv) has been used as part of salvage regimens or as post HCT consolidation with improved remission rates [11] , [12] , [13] , [14] , [15] . Patients with R/R cHL who achieve less than partial response (PR) following first line platinum-based salvage chemotherapy traditionally have poor outcomes and they represent a big challenge as standard approaches are lacking [16] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era

Abuelgasim¹,

Ghazi²,

Alahmari³

et al. 2021

Leukemia Research Reports

Self Cite

View full text Add to dashboard Cite

Relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients refractory to first line salvage have poor outcomes. Herein we report the outcome of R/R cHL patients requiring ≥two vs. one line in the era of chemo-immunotherapy. Among 55 R/R cHL patients, 33 (60%) required one, 22 (40%) required ≥two lines. At 2 years, the estimated PFS and OS for patients requiring one vs. ≥two lines was 71.2% (50.1–84.7) vs. 51.9% (27.6–71.6), p = 0.16 and 84.6% (63–94) vs. 84% (58–95), p = 0.88, respectively. Patients requiring ≥two salvage lines prior to HCT can achieve comparable outcomes to those requiring one, possibly due to brentuximab vedotin leading to higher CMR rates.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era

Abuelgasim¹,

Ghazi²,

Alahmari³

et al. 2021

Leukemia Research Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…108,110,114,115 In a recent retrospective trial, the combination of BV with IGEV in rr-cHL patients (half of them receiving it as a subsequent salvage line) led to a more favorable SCT outcome by improving metabolic status prior to SCT in this high-risk clinical setting. 109 The results of all phase II trials of BV plus sequential or concurrent established salvage regimens are summarized in Table 2. Almost all these trials provided high metabolic CR rates, typically 70-80%, which appear higher than those achieved with the corresponding salvage regimens without BV.…”

Section: New Conventional Salvage Chemotherapy Regimensmentioning

confidence: 99%

“…This strategy is currently restricted to the incorporation of BV in second-line strategies, as summarized in Table 2. 99–110 Other combinations, such as bortezomib-ICE, panobinostat-ICE and bortezomib-IGEV, were evaluated but were not further developed, with both bortezomib-based combinations failing to prove superior to the corresponding conventional regimens in randomised phase II trials. 76,97,98…”

Section: Second-line Therapy For Classical Hodgkin Lymphomamentioning

confidence: 99%

See 1 more Smart Citation

Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies

Vassilakopoulos

Asimakopoulos

Konstantopoulos

et al. 2020

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (rr-cHL) has improved considerably in recent years owing to the approval of highly active novel agents such as brentuximab vedotin and Programmed Death-1 (PD-1) inhibitors. Although no randomized trials have been conducted to provide formal proof, it is almost undisputable that the survival of these patients has been prolonged. As autologous stem-cell transplantation (SCT) remains the standard of care for second-line therapy of most patients with rr-cHL, optimization of second-line regimens with the use of brentuximab vedotin, or, in the future, checkpoint inhibitors, is promising to increase both the eligibility rate for transplant and the final outcome. The need for subsequent therapy, and especially allogeneic SCT, can be reduced with brentuximab vedotin consolidation for 1 year, while pembrolizumab is also being tested in this setting. Several other drug categories appear to be active in rr-cHL, but their development has been delayed by the appearance of brentuximab vedotin, nivolumab and pembrolizumab, which have dominated the field of rr-cHL treatment in the last 5 years. Combinations of active drugs in chemo-free approaches may further increase efficacy and hopefully reduce toxicity in rr-cHL, but are still under development.

show abstract

SOHO State of the Art Updates and Next Questions | From Biology to Therapy: Progress in Hodgkin Lymphoma

Chohan

Ansell

2023

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma

Cited by 16 publications

References 14 publications

Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era

Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era

Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies

SOHO State of the Art Updates and Next Questions | From Biology to Therapy: Progress in Hodgkin Lymphoma

Contact Info

Product

Resources

About